We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

70 hedge funds and large institutions have $338M invested in Stemline Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

84% more capital invested

Capital invested by funds: $184M → $338M (+$154M)

25% more funds holding

Funds holding: 56 → 70 (+14)

5% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 21

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
70
Holders Change
+14
Holders Change %
+25%
% of All Funds
2.27%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
22
Reduced
21
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCA
SAC Capital Advisors
Connecticut
+$10.1M
2
Goldman Sachs
Goldman Sachs
New York
+$5.71M
3
Citadel Advisors
Citadel Advisors
Florida
+$5.11M
4
Franklin Resources
Franklin Resources
California
+$5.1M
5
DCM
Driehaus Capital Management
Illinois
+$4.24M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$16.4M
2
Neuberger Berman Group
Neuberger Berman Group
New York
-$5.43M
3
VAM
Visium Asset Management
New York
-$4.89M
4
BBA
Baker Bros. Advisors
New York
-$3.25M
5
FCM
Farallon Capital Management
California
-$2.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$1.69M -$345K -10,564 -22%
Invesco
27
Invesco
Georgia
$1.57M +$1.13M +34,718 New
Morgan Stanley
28
Morgan Stanley
New York
$1.43M -$23.5K -720 -2%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$1.43M -$1.49M -45,644 -59%
BIM
30
BlackRock Investment Management
Delaware
$1.17M +$68.5K +2,099 +9%
Allianz Asset Management
31
Allianz Asset Management
Germany
$1.16M +$832K +25,500 New
EIM
32
Essex Investment Management
Massachusetts
$894K +$82K +2,515 +15%
TD Asset Management
33
TD Asset Management
Ontario, Canada
$856K +$45.7K +1,400 +8%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$851K +$613K +18,800 New
RFC
35
Russell Frank Company
Washington
$775K -$352K -10,782 -37%
HVC
36
Healthcare Value Capital
New Jersey
$746K +$537K +16,464 New
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$740K +$13K +400 +3%
BA
38
BlackRock Advisors
Delaware
$706K +$373K +11,446 +277%
WMSA
39
Weiss Multi-Strategy Advisers
New York
$679K +$489K +15,000 New
CAM
40
ClariVest Asset Management
California
$672K +$484K +14,834 New
Charles Schwab
41
Charles Schwab
California
$613K – – –
TA
42
Teachers Advisors
New York
$578K +$24.5K +752 +6%
Deutsche Bank
43
Deutsche Bank
Germany
$549K +$215K +6,579 +118%
TAM
44
Tocqueville Asset Management
New York
$544K -$202K -6,200 -34%
William Blair & Company
45
William Blair & Company
Illinois
$408K +$294K +9,022 New
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$379K +$273K +8,359 New
MLICM
47
Metropolitan Life Insurance Company (MetLife)
New York
$361K – – –
VOYA Investment Management
48
VOYA Investment Management
Georgia
$354K +$255K +7,815 New
NFA
49
Nationwide Fund Advisors
Ohio
$330K +$142K +4,368 +149%
Millennium Management
50
Millennium Management
New York
$308K -$62K -1,900 -22%
1
2
3

STML Hedge Fund Activity: Q3 2013 in Review

70 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2013, worth a combined $338M — up 84% from $184M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new STML positions and 5 closed out — a net gain of 15 holders — while 22 added to existing stakes and 21 trimmed.

The largest buyer was SAC Capital Advisors, adding an estimated $10.1M. The largest seller was Perceptive Advisors, cutting an estimated $16.4M.

  • 70 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2013, up from 56 in Q2 2013.
  • Funds reported $338M of Stemline Therapeutics, Inc. stock for Q3 2013, up 84% quarter-over-quarter.
  • 20 funds opened new Stemline Therapeutics, Inc. positions in Q3 2013 and 5 closed out, a net change of +15 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q3 2013 was SAC Capital Advisors, an estimated $10.1M added.
  • The largest Stemline Therapeutics, Inc. seller in Q3 2013 was Perceptive Advisors, an estimated $16.4M sold.

Based on aggregated 13F filings for Q3 2013.